Silva M R, Ascensao J L
Portuguese Institute of Oncology, Lisbon, Portugal.
J Hematother. 1995 Dec;4(6):563-70. doi: 10.1089/scd.1.1995.4.563.
Autologous bone marrow transplantation (ABMT) is widely used to treat hematologic and non-hematologic malignancies. In an attempt to reduce potential neoplastic contamination of the graft, pharmacologic purging with cyclophosphamide derivatives and etoposide (VP16) is often used. Trilineage hemopoietic engraftment is seen following ABMT with VP16-purged bone marrow (BM), but little is known about immune reconstitution in this setting. We studied the in vitro development of natural killer (NK) cells from VP16-purged BM. These cells, defined by phenotypic and functional criteria, undergo rapid regeneration, expansion, and maturation in the presence of interleukin 2 (IL-2). VP16 seems to spare subsets of NK cells, and this cell lineage develops rapidly in VP16-treated BM cultures from patients with acute myelogenous leukemia (AML) and healthy donors. Since relapse rates remain high, immunotherapy following ABMT with purged BM may be useful and should be considered in these patients.
自体骨髓移植（ABMT）被广泛用于治疗血液系统和非血液系统恶性肿瘤。为了减少移植物潜在的肿瘤污染，常使用环磷酰胺衍生物和依托泊苷（VP16）进行药物净化。使用VP16净化骨髓（BM）进行ABMT后可见三系造血植入，但在这种情况下对免疫重建了解甚少。我们研究了来自VP16净化BM的自然杀伤（NK）细胞的体外发育。这些根据表型和功能标准定义的细胞，在白细胞介素2（IL-2）存在的情况下经历快速再生、扩增和成熟。VP16似乎使NK细胞亚群得以保留，并且在急性髓性白血病（AML）患者和健康供体的VP16处理的BM培养物中，该细胞谱系迅速发育。由于复发率仍然很高，ABMT后使用净化BM进行免疫治疗可能有用，这些患者应予以考虑。
